A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

Stopped Discontinued based on the absence of positive trends on clinical endpoints.

Conditions

• Tay-Sachs Disease
• Sandhoff Disease

Interventions

• DRUG: venglustat GZ402671
• DRUG: placebo

Sponsor

Genzyme, a Sanofi Company